A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.

Journal Article (Journal Article)

Targeting multiple regulators of tumor angiogenesis have the potential to improve treatment efficacy. Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor and ABT-510 is a synthetic analog of thrombospondin, an endogenous angiogenesis inhibitor. Dual inhibition may result in additional benefit. We evaluated the safety, tolerability, and efficacy of the combination of bevacizumab plus ABT-510 in patients with refractory solid tumors. We also explored the effects of these agents on plasma-based biomarkers and wound angiogenesis. Thirty-four evaluable subjects were enrolled and received study drug. Therapy was well tolerated; minimal treatment-related grade 3/4 toxicity was observed. One patient treated at dose level 1 had a partial response and five other patients treated at the recommended phase II dose had prolonged stable disease for more than 1 year. Biomarker evaluation revealed increased levels of D-dimer, von Willebrand factor, placental growth factor, and stromal-derived factor 1 in response to treatment with the combination of bevacizumab and ABT-510. Data suggest that continued evaluation of combination antiangiogenesis therapies may be clinically useful.

Full Text

Duke Authors

Cited Authors

  • Uronis, HE; Cushman, SM; Bendell, JC; Blobe, GC; Morse, MA; Nixon, AB; Dellinger, A; Starr, MD; Li, H; Meadows, K; Gockerman, J; Pang, H; Hurwitz, HI

Published Date

  • June 2013

Published In

Volume / Issue

  • 2 / 3

Start / End Page

  • 316 - 324

PubMed ID

  • 23930208

Pubmed Central ID

  • PMC3699843

Electronic International Standard Serial Number (EISSN)

  • 2045-7634

Digital Object Identifier (DOI)

  • 10.1002/cam4.65


  • eng

Conference Location

  • United States